P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

• Justin M. Watts,
• Anthony M. Hunter,
• Alessandra Iurlo,
• Blanca Xicoy,
• Francesca Palandri,
• Brandi Reeves,
• Alessandro Vannucchi,
• Prithviraj Bose,
• Rosa Ayala Diaz,
• Anna B. Halpern,
• Xuejun Chen,
• Francis Seguy,
• Feng Zhou,
• Fred Zheng,
• Pankit Vachhani

Affiliations

Justin M. Watts

1 Sylvester Cancer Center, University of Miami, Miami, United States

Anthony M. Hunter

2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, United States

Alessandra Iurlo

3 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Blanca Xicoy

4 Hospital Germans Trias i Pujol, Institut Català d’Oncologia, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain

Francesca Palandri

5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

Brandi Reeves

6 University of North Carolina School of Medicine, Chapel Hill, United States

Alessandro Vannucchi

7 AOU Careggi, University of Florence, Florence, Italy

Prithviraj Bose

8 The University of Texas MD Anderson Cancer Center, Houston, United States

Rosa Ayala Diaz

9 Hospital Universitario 12 de Octubre, Madrid, Spain

Anna B. Halpern

10 University of Washington, Seattle, United States

Xuejun Chen

12 Incyte Corporation, Wilmington, United States

Francis Seguy

13 Incyte Biosciences International Sàrl, Morges, Switzerland

Feng Zhou

12 Incyte Corporation, Wilmington, United States

Fred Zheng

12 Incyte Corporation, Wilmington, United States

Pankit Vachhani

14 O’Neal Comprehensive Cancer Center at UAB, Birmingham, United States